ProShare Advisors’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-2,342
| Closed | -$45K | – | 2122 |
|
|
2022
Q1 | $45K | Sell |
2,342
-558
| -19% | -$8.78K | ﹤0.01% | 2119 |
|
|
2021
Q4 | $52K | Buy |
2,900
+90
| +3% | +$2.7K | ﹤0.01% | 2281 |
|
|
2021
Q3 | $104K | Sell |
2,810
-480
| -15% | -$21.3K | ﹤0.01% | 1910 |
|
|
2021
Q2 | $196K | Buy |
3,290
+414
| +14% | +$25.1K | ﹤0.01% | 2152 |
|
|
2021
Q1 | $193K | Buy |
2,876
+809
| +39% | +$63.3K | ﹤0.01% | 2053 |
|
|
2020
Q4 | $125K | Buy |
2,067
+610
| +42% | +$41.6K | ﹤0.01% | 1954 |
|
|
2020
Q3 | $115K | Sell |
1,457
-53
| -4% | -$4.22K | ﹤0.01% | 1513 |
|
|
2020
Q2 | $94K | Buy |
1,510
+504
| +50% | +$29.3K | ﹤0.01% | 1574 |
|
|
2020
Q1 | $53K | Sell |
1,006
-767
| -43% | -$76K | ﹤0.01% | 1116 |
|
|
2019
Q4 | $215K | Buy |
1,773
+18
| +1% | +$2.59K | ﹤0.01% | 1542 |
|
|
2019
Q3 | $318K | Sell |
1,755
-44
| -2% | -$6.2K | ﹤0.01% | 1196 |
|
|
2019
Q2 | $234K | Sell |
1,799
-241
| -12% | -$43.2K | ﹤0.01% | 1350 |
|
|
2019
Q1 | $497K | Buy |
2,040
+42
| +2% | +$11.1K | ﹤0.01% | 1023 |
|
|
2018
Q4 | $381K | Sell |
1,998
-369
| -16% | -$90K | ﹤0.01% | 1042 |
|
|
2018
Q3 | $776K | Buy |
2,367
+104
| +5% | +$31.9K | 0.01% | 930 |
|
|
2018
Q2 | $706K | Sell |
2,263
-162
| -7% | -$49.5K | ﹤0.01% | 970 |
|
|
2018
Q1 | $590K | Sell |
2,425
-399
| -14% | -$112K | ﹤0.01% | 1036 |
|
|
2017
Q4 | $853K | Buy |
2,824
+2,609
| +1,213% | +$726K | 0.01% | 898 |
|
|
2017
Q3 | $57K | Sell |
215
-61
| -22% | -$17.6K | ﹤0.01% | 1340 |
|
|
2017
Q2 | $73K | Sell |
276
-70
| -20% | -$17.5K | ﹤0.01% | 1408 |
|
|
2017
Q1 | $124K | Sell |
346
-136
| -28% | -$42.1K | ﹤0.01% | 1500 |
|
|
2016
Q4 | $139K | Buy |
482
+186
| +63% | +$57.6K | ﹤0.01% | 1654 |
|
|
2016
Q3 | $101K | Sell |
296
-71
| -19% | -$25.9K | ﹤0.01% | 1418 |
|
|
2016
Q2 | $156K | Buy |
367
+15
| +4% | +$6.18K | ﹤0.01% | 1468 |
|
|
2016
Q1 | $113K | Sell |
352
-18
| -5% | -$6.14K | ﹤0.01% | 1503 |
|
|
2015
Q4 | $192K | Buy |
370
+128
| +53% | +$47.3K | ﹤0.01% | 1553 |
|
|
2015
Q3 | $71K | Sell |
242
-79
| -25% | -$28.1K | ﹤0.01% | 1401 |
|
|
2015
Q2 | $126K | Sell |
321
-138
| -30% | -$48.7K | ﹤0.01% | 1567 |
|
|
2015
Q1 | $139K | Sell |
459
-4
| -0.9% | -$976 | ﹤0.01% | 1771 |
|
|
2014
Q4 | $103K | Sell |
463
-393
| -46% | -$81.1K | ﹤0.01% | 1837 |
|
|
2014
Q3 | $199K | Sell |
856
-124
| -13% | -$31.2K | ﹤0.01% | 1977 |
|
|
2014
Q2 | $217K | Sell |
980
-767
| -44% | -$171K | ﹤0.01% | 2121 |
|
|
2014
Q1 | $551K | Buy |
+1,747
| New | +$556K | 0.01% | 1794 |
|
|
2013
Q4 | – | Sell |
-986
| Closed | -$144K | – | 1850 |
|
|
2013
Q3 | $144K | Buy |
+986
| New | +$119K | ﹤0.01% | 2307 |
|
Other funds holding TXMD
RCMNY
E
GF
ProShare Advisors's TXMD Position: Q2 2022 in Review
ProShare Advisors sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 2,342 shares — an estimated $45K sold.
ProShare Advisors first reported a position in TXMD in Q3 2013 and held it in 34 quarters. The position peaked at $853K in Q4 2017. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.
- ProShare Advisors reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
- ProShare Advisors sold 2,342 TherapeuticsMD shares in Q2 2022, an estimated $45K.
- ProShare Advisors first reported a position in TherapeuticsMD in Q3 2013 and held it in 34 quarters.
- ProShare Advisors's TherapeuticsMD position peaked at $853K in Q4 2017.
- 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.
Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.